haloperidol sold brand name haldol among others typical antipsychotic medication
haloperidol used treatment schizophrenia tic tourette syndrome mania bipolar disorder delirium agitation acute psychosis hallucination alcohol withdrawal
long-acting formulation may used injection every four week people schizophrenia related illness either forget refuse take medication mouth
haloperidol may result movement disorder known tardive dyskinesia may permanent
neuroleptic malignant syndrome qt interval prolongation may occur
older people psychosis due dementia result increased risk death
haloperidol wa discovered paul janssen prepared part structure-activity relationship investigation analog pethidine meperidine
wa commonly prescribed medication united state one million prescriptions
acute psychosis drug-induced psychosis caused amphetamine ketamine phencyclidine psychosis associated high fever metabolic disease
evidence however ha found haloperidol worsen psychosis due psilocybin
treatment neurological disorder tic disorder tourette syndrome chorea
treatment severe nausea emesis postoperative palliative care especially palliating adverse effect radiation therapy chemotherapy oncology
also used first line antiemetic acute cannabis hyperemesis syndromehaloperidol wa considered indispensable treating psychiatric emergency situation although newer atypical drug gained greater role number situation outlined series consensus review published and
wa effective ziprasidone chlorpromazine asenapine approximately effective quetiapine aripiprazole le effective paliperidone
data animal experiment indicate haloperidol teratogenic embryotoxic high doses
report pregnant woman revealed possible damage fetus although woman exposed multiple drug pregnancy
addition report indicate neonate exposed antipsychotic drug risk extrapyramidal andor withdrawal symptom following delivery agitation hypertonia hypotonia tremor somnolence respiratory distress feeding disorder
following accepted general principle haloperidol given pregnancy benefit mother clearly outweighs potential fetal risk
study examined impact haloperidol exposure breastfed infant case adverse effect infant growth development
long-term treatment chronic psychiatric disorder daily dose reduced lowest level needed maintenance remission
addition long-term use routine monitoring including measurement bmi blood pressure fasting blood sugar lipid recommended due risk side effects
form therapy psychotherapy occupational therapyergotherapy social rehabilitation instituted properly
clinical response wa associated least occupancy receptor greater wa likely cause hyperprolactinaemia associated extrapyramidal side effects
dos haloperidol greater mg increased risk side effect without improving efficacy
maintenance treatment schizophrenia international consensus conference recommended reduction dosage every month minimal maintenance dose established
depot form also available injected deeply intramuscularly regular intervals
depot form suitable initial treatment suitable patient demonstrated inconsistency oral dosagesthe decanoate ester haloperidol haloperidol decanoate trade name haldol decanoate halomonth neoperidole ha much longer duration action often used people known noncompliant oral medication
dose given intramuscular injection every two four weeks
iupac name haloperidol decanoate chlorophenyl- fluorophenyl- oxobutylpiperidin- yl decanoate
topical formulation haloperidol used treatment nausea research doe indicate therapy effective alternatives
haloperidol high-potency typical antipsychotic tends produce significant extrapyramidal side effects
according meta-analysis comparative efficacy tolerability antipsychotic drug wa prone causing extrapyramidal side effects
anticholinergic side effect adverse effect le common lower-potency typical antipsychotic chlorpromazine thioridazine
somnolence particularly prominent side effect supported result aforementioned meta-analysisunknown frequency
known heart disease combined tend towards cardiac arresta multiple-year study suggested drug neuroleptic antipsychotic drug commonly given people alzheimer's mild behavioral problem often make condition worse withdrawal wa even beneficial cognitive functional measures
elderly patient dementia-related psychosis analysis trial showed risk death group patient wa time placebo-treated patients
clear extent observation attributed antipsychotic drug rather characteristic patients
impaired liver function haloperidol metabolized eliminated mainly liver
patient hyperthyroidism action haloperidol intensified side effect likely
patient special risk development qt prolongation hypokalemia concomitant use drug causing qt prolongation
patient history leukopenia complete blood count monitored frequently first month therapy discontinuation drug considered first sign clinically significant decline white blood cells
pre-existing parkinson's disease dementia lewy bodiesamiodarone q-tc interval prolongation potentially dangerous change heart rhythm
amphetamine methylphenidate counteracts increased action norepinephrine dopamine patient narcolepsy addadhd
epinephrine action antagonized paradoxical decrease blood pressure may result
lithium rare case following symptom noted encephalopathy early late extrapyramidal side effect neurologic symptom coma
methyldopa increased risk extrapyramidal side effect unwanted central effects
central depressant alcohol tranquilizer narcotic action side effect drug sedation respiratory depression increased
particular dos concomitantly used opioids chronic pain reduced by
drug metabolized cypa enzyme system inducer carbamazepine phenobarbital rifampicin decrease plasma level inhibitor quinidine buspirone fluoxetine increase plasma levels
tricyclic antidepressant metabolism elimination tricyclic significantly decreased increased toxicity noted anticholinergic cardiovascular side effect lowering seizure thresholdthe british national formulary recommends gradual withdrawal discontinuing antipsychotic avoid acute withdrawal syndrome rapid relapse
symptom withdrawal commonly include nausea vomiting loss appetite
symptom may include restlessness increased sweating trouble sleeping
le commonly may feeling world spinning numbness muscle pains
anticholinergic side effect dry mouth constipation paralytic ileus difficulty urinating decreased perspiration
coma severe case accompanied respiratory depression massive hypotension shock
rarely serious ventricular arrhythmia torsades de pointes without prolonged qt-time
severe extrapyramidal side effect muscle rigidity tremor akathisia etctreatment mostly symptomatic involves intensive care stabilization vital functions
early detected case oral overdose induction emesis gastric lavage use activated charcoal tried
case severe overdose antidote bromocriptine ropinirole may used treat extrapyramidal effect caused haloperidol acting dopamine receptor agonists
ecg vital sign monitored especially qt prolongation severe arrhythmia treated antiarrhythmic measures
overdose haloperidol fatal general prognosis overdose good provided person ha survived initial phase
haloperidol typical butyrophenone type antipsychotic exhibit high affinity dopamine receptor antagonism slow receptor dissociation kinetics
drug bind preferentially receptor low dose ed mgkg respectively ht receptor higher dose ed mgkg
given antagonism receptor beneficial positive symptom schizophrenia antagonism ht receptor negative symptom characteristic underlies haloperidol's greater effect delusion hallucination manifestation psychosis
haloperidol's negligible affinity histamine h receptor muscarinic acetylcholine receptor yield antipsychotic lower incidence sedation weight gain orthostatic hypotension though higher rate treatment emergent extrapyramidal symptoms
nrnrb subunit containing nmda receptor antagonist ifenprodil site ic nmthe bioavailability oral haloperidol range from
however wide variance reported mean tmax different study ranging hour hour respectively
drug well rapidly absorbed high bioavailability injected intramuscularly
decanoate injectable formulation intramuscular administration intended used intravenously
plasma concentration haloperidol decanoate reach peak six day injection falling thereafter approximate half-life three weeks
bioavailability intravenous iv injection rapid onset action seen within seconds
plasma level five microgram per liter typically seen therapeutic response ulrich et al
determination plasma level rarely used calculate dose adjustment useful check compliance
concentration haloperidol brain tissue fold higher compared blood levels
slowly eliminated brain tissue may explain slow disappearance side effect medication stopped
haloperidol heavily protein bound human plasma free fraction to
also extensively metabolized liver administered dose excreted unchanged urine
greatest proportion hepatic clearance glucuronidation followed reduction cyp-mediated oxidation primarily cypa
wa developed belgian company janssen pharmaceutica submitted first clinical trial belgium later year
food drug administration fda april wa later marketed us
haloperidol relatively inexpensive fold le expensive newer antipsychotics
sold tradenames aloperidin bioperidolo brotopon dozic duraperidol germany einalon eukystol haldol common tradename u uk halol halosten keselan linton peluces serenace sigaperidol
haloperidol also used many different kind animal nonselective tranquilization diminishing behavioral arousal veterinary setting including captivity management